58

Associazione Medici Endocrinologi€¦ · 417 patients with metastatic, RAI-resistant DTC, progression last 14 months Randomization: Sorafenib 400 mg x 2 or placebo (cross-over) Cross-over

Download PDF Report

Upload
others
View
2
Download
0

Embed Size (px)

Citation preview

Page 1: Associazione Medici Endocrinologi€¦ · 417 patients with metastatic, RAI-resistant DTC, progression last 14 months Randomization: Sorafenib 400 mg x 2 or placebo (cross-over) Cross-over

Page 2: Associazione Medici Endocrinologi€¦ · 417 patients with metastatic, RAI-resistant DTC, progression last 14 months Randomization: Sorafenib 400 mg x 2 or placebo (cross-over) Cross-over

Page 3: Associazione Medici Endocrinologi€¦ · 417 patients with metastatic, RAI-resistant DTC, progression last 14 months Randomization: Sorafenib 400 mg x 2 or placebo (cross-over) Cross-over

Page 4: Associazione Medici Endocrinologi€¦ · 417 patients with metastatic, RAI-resistant DTC, progression last 14 months Randomization: Sorafenib 400 mg x 2 or placebo (cross-over) Cross-over

Page 5: Associazione Medici Endocrinologi€¦ · 417 patients with metastatic, RAI-resistant DTC, progression last 14 months Randomization: Sorafenib 400 mg x 2 or placebo (cross-over) Cross-over

Page 6: Associazione Medici Endocrinologi€¦ · 417 patients with metastatic, RAI-resistant DTC, progression last 14 months Randomization: Sorafenib 400 mg x 2 or placebo (cross-over) Cross-over

Page 7: Associazione Medici Endocrinologi€¦ · 417 patients with metastatic, RAI-resistant DTC, progression last 14 months Randomization: Sorafenib 400 mg x 2 or placebo (cross-over) Cross-over

Page 8: Associazione Medici Endocrinologi€¦ · 417 patients with metastatic, RAI-resistant DTC, progression last 14 months Randomization: Sorafenib 400 mg x 2 or placebo (cross-over) Cross-over

Page 9: Associazione Medici Endocrinologi€¦ · 417 patients with metastatic, RAI-resistant DTC, progression last 14 months Randomization: Sorafenib 400 mg x 2 or placebo (cross-over) Cross-over

Page 10: Associazione Medici Endocrinologi€¦ · 417 patients with metastatic, RAI-resistant DTC, progression last 14 months Randomization: Sorafenib 400 mg x 2 or placebo (cross-over) Cross-over

Page 11: Associazione Medici Endocrinologi€¦ · 417 patients with metastatic, RAI-resistant DTC, progression last 14 months Randomization: Sorafenib 400 mg x 2 or placebo (cross-over) Cross-over

Page 12: Associazione Medici Endocrinologi€¦ · 417 patients with metastatic, RAI-resistant DTC, progression last 14 months Randomization: Sorafenib 400 mg x 2 or placebo (cross-over) Cross-over

Page 13: Associazione Medici Endocrinologi€¦ · 417 patients with metastatic, RAI-resistant DTC, progression last 14 months Randomization: Sorafenib 400 mg x 2 or placebo (cross-over) Cross-over

Page 14: Associazione Medici Endocrinologi€¦ · 417 patients with metastatic, RAI-resistant DTC, progression last 14 months Randomization: Sorafenib 400 mg x 2 or placebo (cross-over) Cross-over

Page 15: Associazione Medici Endocrinologi€¦ · 417 patients with metastatic, RAI-resistant DTC, progression last 14 months Randomization: Sorafenib 400 mg x 2 or placebo (cross-over) Cross-over

Page 16: Associazione Medici Endocrinologi€¦ · 417 patients with metastatic, RAI-resistant DTC, progression last 14 months Randomization: Sorafenib 400 mg x 2 or placebo (cross-over) Cross-over

Page 17: Associazione Medici Endocrinologi€¦ · 417 patients with metastatic, RAI-resistant DTC, progression last 14 months Randomization: Sorafenib 400 mg x 2 or placebo (cross-over) Cross-over

Page 18: Associazione Medici Endocrinologi€¦ · 417 patients with metastatic, RAI-resistant DTC, progression last 14 months Randomization: Sorafenib 400 mg x 2 or placebo (cross-over) Cross-over

Page 19: Associazione Medici Endocrinologi€¦ · 417 patients with metastatic, RAI-resistant DTC, progression last 14 months Randomization: Sorafenib 400 mg x 2 or placebo (cross-over) Cross-over

Page 20: Associazione Medici Endocrinologi€¦ · 417 patients with metastatic, RAI-resistant DTC, progression last 14 months Randomization: Sorafenib 400 mg x 2 or placebo (cross-over) Cross-over

Page 21: Associazione Medici Endocrinologi€¦ · 417 patients with metastatic, RAI-resistant DTC, progression last 14 months Randomization: Sorafenib 400 mg x 2 or placebo (cross-over) Cross-over

Page 22: Associazione Medici Endocrinologi€¦ · 417 patients with metastatic, RAI-resistant DTC, progression last 14 months Randomization: Sorafenib 400 mg x 2 or placebo (cross-over) Cross-over

Page 23: Associazione Medici Endocrinologi€¦ · 417 patients with metastatic, RAI-resistant DTC, progression last 14 months Randomization: Sorafenib 400 mg x 2 or placebo (cross-over) Cross-over

Page 24: Associazione Medici Endocrinologi€¦ · 417 patients with metastatic, RAI-resistant DTC, progression last 14 months Randomization: Sorafenib 400 mg x 2 or placebo (cross-over) Cross-over

Page 25: Associazione Medici Endocrinologi€¦ · 417 patients with metastatic, RAI-resistant DTC, progression last 14 months Randomization: Sorafenib 400 mg x 2 or placebo (cross-over) Cross-over

Page 26: Associazione Medici Endocrinologi€¦ · 417 patients with metastatic, RAI-resistant DTC, progression last 14 months Randomization: Sorafenib 400 mg x 2 or placebo (cross-over) Cross-over

Page 27: Associazione Medici Endocrinologi€¦ · 417 patients with metastatic, RAI-resistant DTC, progression last 14 months Randomization: Sorafenib 400 mg x 2 or placebo (cross-over) Cross-over

Page 28: Associazione Medici Endocrinologi€¦ · 417 patients with metastatic, RAI-resistant DTC, progression last 14 months Randomization: Sorafenib 400 mg x 2 or placebo (cross-over) Cross-over

Page 29: Associazione Medici Endocrinologi€¦ · 417 patients with metastatic, RAI-resistant DTC, progression last 14 months Randomization: Sorafenib 400 mg x 2 or placebo (cross-over) Cross-over

Page 30: Associazione Medici Endocrinologi€¦ · 417 patients with metastatic, RAI-resistant DTC, progression last 14 months Randomization: Sorafenib 400 mg x 2 or placebo (cross-over) Cross-over

Page 31: Associazione Medici Endocrinologi€¦ · 417 patients with metastatic, RAI-resistant DTC, progression last 14 months Randomization: Sorafenib 400 mg x 2 or placebo (cross-over) Cross-over

Page 32: Associazione Medici Endocrinologi€¦ · 417 patients with metastatic, RAI-resistant DTC, progression last 14 months Randomization: Sorafenib 400 mg x 2 or placebo (cross-over) Cross-over

Page 33: Associazione Medici Endocrinologi€¦ · 417 patients with metastatic, RAI-resistant DTC, progression last 14 months Randomization: Sorafenib 400 mg x 2 or placebo (cross-over) Cross-over

Page 34: Associazione Medici Endocrinologi€¦ · 417 patients with metastatic, RAI-resistant DTC, progression last 14 months Randomization: Sorafenib 400 mg x 2 or placebo (cross-over) Cross-over

Page 35: Associazione Medici Endocrinologi€¦ · 417 patients with metastatic, RAI-resistant DTC, progression last 14 months Randomization: Sorafenib 400 mg x 2 or placebo (cross-over) Cross-over

Page 36: Associazione Medici Endocrinologi€¦ · 417 patients with metastatic, RAI-resistant DTC, progression last 14 months Randomization: Sorafenib 400 mg x 2 or placebo (cross-over) Cross-over

Page 37: Associazione Medici Endocrinologi€¦ · 417 patients with metastatic, RAI-resistant DTC, progression last 14 months Randomization: Sorafenib 400 mg x 2 or placebo (cross-over) Cross-over

Page 38: Associazione Medici Endocrinologi€¦ · 417 patients with metastatic, RAI-resistant DTC, progression last 14 months Randomization: Sorafenib 400 mg x 2 or placebo (cross-over) Cross-over

Page 39: Associazione Medici Endocrinologi€¦ · 417 patients with metastatic, RAI-resistant DTC, progression last 14 months Randomization: Sorafenib 400 mg x 2 or placebo (cross-over) Cross-over

Page 40: Associazione Medici Endocrinologi€¦ · 417 patients with metastatic, RAI-resistant DTC, progression last 14 months Randomization: Sorafenib 400 mg x 2 or placebo (cross-over) Cross-over

Page 41: Associazione Medici Endocrinologi€¦ · 417 patients with metastatic, RAI-resistant DTC, progression last 14 months Randomization: Sorafenib 400 mg x 2 or placebo (cross-over) Cross-over

Page 42: Associazione Medici Endocrinologi€¦ · 417 patients with metastatic, RAI-resistant DTC, progression last 14 months Randomization: Sorafenib 400 mg x 2 or placebo (cross-over) Cross-over

Page 43: Associazione Medici Endocrinologi€¦ · 417 patients with metastatic, RAI-resistant DTC, progression last 14 months Randomization: Sorafenib 400 mg x 2 or placebo (cross-over) Cross-over

Page 44: Associazione Medici Endocrinologi€¦ · 417 patients with metastatic, RAI-resistant DTC, progression last 14 months Randomization: Sorafenib 400 mg x 2 or placebo (cross-over) Cross-over

Page 45: Associazione Medici Endocrinologi€¦ · 417 patients with metastatic, RAI-resistant DTC, progression last 14 months Randomization: Sorafenib 400 mg x 2 or placebo (cross-over) Cross-over

Page 46: Associazione Medici Endocrinologi€¦ · 417 patients with metastatic, RAI-resistant DTC, progression last 14 months Randomization: Sorafenib 400 mg x 2 or placebo (cross-over) Cross-over

Page 47: Associazione Medici Endocrinologi€¦ · 417 patients with metastatic, RAI-resistant DTC, progression last 14 months Randomization: Sorafenib 400 mg x 2 or placebo (cross-over) Cross-over

Page 48: Associazione Medici Endocrinologi€¦ · 417 patients with metastatic, RAI-resistant DTC, progression last 14 months Randomization: Sorafenib 400 mg x 2 or placebo (cross-over) Cross-over

Page 49: Associazione Medici Endocrinologi€¦ · 417 patients with metastatic, RAI-resistant DTC, progression last 14 months Randomization: Sorafenib 400 mg x 2 or placebo (cross-over) Cross-over

Page 50: Associazione Medici Endocrinologi€¦ · 417 patients with metastatic, RAI-resistant DTC, progression last 14 months Randomization: Sorafenib 400 mg x 2 or placebo (cross-over) Cross-over

Page 51: Associazione Medici Endocrinologi€¦ · 417 patients with metastatic, RAI-resistant DTC, progression last 14 months Randomization: Sorafenib 400 mg x 2 or placebo (cross-over) Cross-over

Page 52: Associazione Medici Endocrinologi€¦ · 417 patients with metastatic, RAI-resistant DTC, progression last 14 months Randomization: Sorafenib 400 mg x 2 or placebo (cross-over) Cross-over

Page 53: Associazione Medici Endocrinologi€¦ · 417 patients with metastatic, RAI-resistant DTC, progression last 14 months Randomization: Sorafenib 400 mg x 2 or placebo (cross-over) Cross-over

Page 54: Associazione Medici Endocrinologi€¦ · 417 patients with metastatic, RAI-resistant DTC, progression last 14 months Randomization: Sorafenib 400 mg x 2 or placebo (cross-over) Cross-over

Page 55: Associazione Medici Endocrinologi€¦ · 417 patients with metastatic, RAI-resistant DTC, progression last 14 months Randomization: Sorafenib 400 mg x 2 or placebo (cross-over) Cross-over

Page 56: Associazione Medici Endocrinologi€¦ · 417 patients with metastatic, RAI-resistant DTC, progression last 14 months Randomization: Sorafenib 400 mg x 2 or placebo (cross-over) Cross-over

Page 57: Associazione Medici Endocrinologi€¦ · 417 patients with metastatic, RAI-resistant DTC, progression last 14 months Randomization: Sorafenib 400 mg x 2 or placebo (cross-over) Cross-over

Page 58: Associazione Medici Endocrinologi€¦ · 417 patients with metastatic, RAI-resistant DTC, progression last 14 months Randomization: Sorafenib 400 mg x 2 or placebo (cross-over) Cross-over

Lenvatinib and sorafenib for treating differentiated

Lenvatinib and sorafenib for treating differentiated

Documents

Pericytes Elicit Resistance to Vemurafenib and Sorafenib ... · Pericytes Elicit Resistance to Vemurafenib and Sorafenib Therapy in Thyroid Carcinoma via the TSP-1/TGFb1 Axis Alessandro

Pericytes Elicit Resistance to Vemurafenib and Sorafenib ... · Pericytes Elicit Resistance to Vemurafenib and Sorafenib Therapy in Thyroid Carcinoma via the TSP-1/TGFb1 Axis Alessandro

Documents

OPTIMIS - Global Observational Study on the use of Sorafenib … · OPTIMIS study design ClinicalTrials.gov NCT01933945 *Includes patients treated with sorafenib at a later time point

OPTIMIS - Global Observational Study on the use of Sorafenib … · OPTIMIS study design ClinicalTrials.gov NCT01933945 *Includes patients treated with sorafenib at a later time point

Documents

Time-Programmed Delivery of Sorafenib and Anti-CD47

Time-Programmed Delivery of Sorafenib and Anti-CD47

Documents

Sorafenib versus Transarterial chemoembolization for

Sorafenib versus Transarterial chemoembolization for

Documents

Acetylsalicylic Acid Governs the Effect of Sorafenib in RAS-Mutant … · Cancer Therapy: Preclinical Acetylsalicylic Acid Governs the Effect of Sorafenib in RAS-Mutant Cancers Heinz

Acetylsalicylic Acid Governs the Effect of Sorafenib in RAS-Mutant … · Cancer Therapy: Preclinical Acetylsalicylic Acid Governs the Effect of Sorafenib in RAS-Mutant Cancers Heinz

Documents

Carboxyamidotriazole Synergizes with Sorafenib to Combat

Carboxyamidotriazole Synergizes with Sorafenib to Combat

Documents

Biological evaluation of a novel sorafenib analogue, t‑CUPMAbstract Sorafenib (Nexavar®) is currently the only FDA-approved small molecule targeted therapy for advanced hepatocellular

Biological evaluation of a novel sorafenib analogue, t‑CUPMAbstract Sorafenib (Nexavar®) is currently the only FDA-approved small molecule targeted therapy for advanced hepatocellular

Documents

Sorafenib decreases proliferation and induces apoptosis of prostate

Sorafenib decreases proliferation and induces apoptosis of prostate

Documents

Kidney Cancer Treatment - Buy Sorafenib 200 Mg Tablet

Kidney Cancer Treatment - Buy Sorafenib 200 Mg Tablet

Health & Medicine

Abbreviated Title: Phase II trial of Sorafenib+Bevacizumab

Abbreviated Title: Phase II trial of Sorafenib+Bevacizumab

Documents

OSU-2S/Sorafenib Synergistic Antitumor Combination against ... · Background: Sorafenib (Nexavar R) is an FDA-approved systemic therapy for advanced hepatocellular carcinoma (HCC)

OSU-2S/Sorafenib Synergistic Antitumor Combination against ... · Background: Sorafenib (Nexavar R) is an FDA-approved systemic therapy for advanced hepatocellular carcinoma (HCC)

Documents

$SoLAT (Sorafenib Lenvatinib alternating treatment): a new … · 2018-10-04 · treatment protocol, SoLAT, using sorafenib and lenvatinib alternatively on refractory thyroid cancer$

SoLAT (Sorafenib Lenvatinib alternating treatment): a new … · 2018-10-04 · treatment protocol, SoLAT, using sorafenib and lenvatinib alternatively on refractory thyroid cancer

Documents

Sorafenib - PerfectionSorafenib Cat. No.: A3009 CAS No.: 284461-73-0 Formula: C21H16ClF3N4O3 M.Wt: 464.82 Synonyms: BAY-43-9006,Sorafenib,Nexavar,sorafenibum Target: Tyrosine Kinase

Sorafenib - PerfectionSorafenib Cat. No.: A3009 CAS No.: 284461-73-0 Formula: C21H16ClF3N4O3 M.Wt: 464.82 Synonyms: BAY-43-9006,Sorafenib,Nexavar,sorafenibum Target: Tyrosine Kinase

Documents

2015 Advances in Hepatocellular Carcinoma Sorafenib-based ...€¦ · process like the later vascular maturation stage. Thus combining dalantercept and sorafenib may achieve enhanced

2015 Advances in Hepatocellular Carcinoma Sorafenib-based ...€¦ · process like the later vascular maturation stage. Thus combining dalantercept and sorafenib may achieve enhanced

Documents

Sorafenib: a multitargeted oral agent for the treatment of …€¦ · Sorafenib: chemistry & preclinical experience Sorafenib (Nexavar®, Bayer Pharmaceuticals Corporation, Leverkusen,

Sorafenib: a multitargeted oral agent for the treatment of …€¦ · Sorafenib: chemistry & preclinical experience Sorafenib (Nexavar®, Bayer Pharmaceuticals Corporation, Leverkusen,

Documents

Sequence‑dependent effect of sorafenib in combination with

Sequence‑dependent effect of sorafenib in combination with

Documents

Sorafenib Side effects and dose adjustment · Sorafenib-Side effects and dose adjustment - Adverse events: prevention and management as key • Patients should be informed to: –

Sorafenib Side effects and dose adjustment · Sorafenib-Side effects and dose adjustment - Adverse events: prevention and management as key • Patients should be informed to: –

Documents

Clinical Policy: Sorafenib (Nexavar)€¦ · Sorafenib (Nexavar ®) is a kinase inhibitor. FDA Approved Indication(s) Nexavar (sorafenib) is indicated for the treatment of: • Unresectable

Clinical Policy: Sorafenib (Nexavar)€¦ · Sorafenib (Nexavar ®) is a kinase inhibitor. FDA Approved Indication(s) Nexavar (sorafenib) is indicated for the treatment of: • Unresectable

Documents

Clinical Policy: Sorafenib (Nexavar) · 2020-04-30 · Clinical Policy: Sorafenib (Nexavar) Reference Number: CP.PHAR.69 Effective Date: 07.01.11 Last Review Date: 05.19 Line of Business:

Clinical Policy: Sorafenib (Nexavar) · 2020-04-30 · Clinical Policy: Sorafenib (Nexavar) Reference Number: CP.PHAR.69 Effective Date: 07.01.11 Last Review Date: 05.19 Line of Business:

Documents

Sorafenib and HCC: Is It All About VEGF?

Sorafenib and HCC: Is It All About VEGF?

Documents

Sorafenib-Induced Hepatocellular Carcinoma Cell Death ...Molecular Medicine in Practice Sorafenib-Induced Hepatocellular Carcinoma Cell Death DependsonReactiveOxygenSpeciesProductionInVitroand

Sorafenib-Induced Hepatocellular Carcinoma Cell Death ...Molecular Medicine in Practice Sorafenib-Induced Hepatocellular Carcinoma Cell Death DependsonReactiveOxygenSpeciesProductionInVitroand

Documents

SorafenibBlockstheRAF/MEK/ERKPathway,InhibitsTumor ...pathways, sorafenib inhibited proliferation and induced apo-ptosis in both HCC cell lines. In the PLC/PRF/5 xenograft model, sorafenib

SorafenibBlockstheRAF/MEK/ERKPathway,InhibitsTumor ...pathways, sorafenib inhibited proliferation and induced apo-ptosis in both HCC cell lines. In the PLC/PRF/5 xenograft model, sorafenib

Documents

Differential Effects of Sorafenib on Liver Versus Tumor

Differential Effects of Sorafenib on Liver Versus Tumor

Documents

Sorafenib-induced defective autophagy promotes cell death by

Sorafenib-induced defective autophagy promotes cell death by

Documents

Raffaele Volpe - Associazione Medici Endocrinologi

Raffaele Volpe - Associazione Medici Endocrinologi

Documents

Influence of the Sorafenib Patients Assistance Program on ... · Influence of the Sorafenib Patients Assistance Program on Treatment ... Perbedaan median kesintasan antara kelompok

Influence of the Sorafenib Patients Assistance Program on ... · Influence of the Sorafenib Patients Assistance Program on Treatment ... Perbedaan median kesintasan antara kelompok

Documents

Therapeutics Sorafenib, a Multikinase Inhibitor, Enhances ...mct.aacrjournals.org/content/molcanther/early/2010/06/18/1535-7163... · Sorafenib, a Multikinase Inhibitor, Enhances

Therapeutics Sorafenib, a Multikinase Inhibitor, Enhances ...mct.aacrjournals.org/content/molcanther/early/2010/06/18/1535-7163... · Sorafenib, a Multikinase Inhibitor, Enhances

Documents

Clinical Policy: Sorafenib (Nexavar) - Superior HealthPlan · 2020-06-10 · Sorafenib (Nexavar ®) is a kinase inhibitor. FDA Approved Indication(s) Nexavar (sorafenib) is indicated

Clinical Policy: Sorafenib (Nexavar) - Superior HealthPlan · 2020-06-10 · Sorafenib (Nexavar ®) is a kinase inhibitor. FDA Approved Indication(s) Nexavar (sorafenib) is indicated

Documents

Addition of Sorafenib to Chemotherapy Improves the Overall ...oncology.tv/Portals/16/Downloadables/Uy sorafenib ASH final.pdf · Internal tandem duplication (ITD) Point mutations

Addition of Sorafenib to Chemotherapy Improves the Overall ...oncology.tv/Portals/16/Downloadables/Uy sorafenib ASH final.pdf · Internal tandem duplication (ITD) Point mutations

Documents